Simone de Leon Martini1, Carolina Beatriz Müller1, Rosalva Thereza Meurer1, Marilda da Cruz Fernandes1, Rodrigo Mariano1, Mariel Barbachan E Silva1, Fábio Klamt1, Cristiano Feijó Andrade1. 1. 1 Programa de Pós-graduação em Ciências Pneumológicas, Universidade Federal do Rio Grande do Sul (UFRGS), 90035-903 Porto Alegre (RS), Brazil ; 2 Laboratório de Pulmão e Vias Aéreas, Hospital de Clínicas de Porto Alegre (HCPA), 90035-903, Porto Alegre (RS), Brazil ; 3 Laboratório de Bioquímica Celular, Departamento de Bioquímica, ICBS/UFRGS, 90035-003 Porto Alegre (RS), Brazil ; 4 Laboratório de Pesquisa em Patologia, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), 90050-170 Porto Alegre (RS), Brazil ; 5 Instituto Nacional de Ciência e Tecnologia-Translational em Medicina (INCT-TM), 90035-903 Porto Alegre (RS), Brazil ; 6 Departamento de Cirurgia Torácica, Hospital de Clínicas de Porto Alegre (HCPA), 90035-903, Porto Alegre (RS), Brazil ; 7 Hospital da Criança Santo Antônio, Santa Casa de Misericórdia de Porto Alegre, 90020-090 Porto Alegre (RS), Brazil.
Abstract
BACKGROUND: Lung cancer is among the most common types of neoplasias, and adenocarcinoma is the most frequent histological type. There is currently an extensive search for prognostic biomarkers of nonsmall cell lung cancer (NSCLC). METHODS: We analyzed the correlation of clinical data and patient survival with the levels of activated extracellular regulatory kinase (ERK) in histological samples of surgically resected early stage lung adenocarcinoma. We randomly selected 36 patients with stage I or II lung adenocarcinoma who underwent pulmonary lobectomy between 1998 and 2004. Patients were divided into the following two groups according to immunohistochemical profile: a group with <15% ERK-positive tumor cells and a group with ≥15% ERK-positive tumor cells. For data comparison, an enrichment analysis of a microarray database was performed (GSE29016, n=72). RESULTS: Activated ERK levels were ≥15% and <15% in 21 (58%) and 15 (42%) patients, respectively. There were no statistically significant differences in age, sex, smoking history, and body mass index (BMI) among the groups stratified by ERK levels. The survival rate was lower in the ERK ≥15% group than in the ERK <15% group (P=0.045). Enrichment analyses showed no correlation between variations in gene expression of ERK in patients with adenocarcinoma and survival rates in patients with stage I and combined stage II + III disease. CONCLUSIONS: Our findings suggest that high ERK positivity in cells from biological samples of lung adenocarcinoma is related with tumor aggressiveness and a poorer prognosis.
BACKGROUND: Lung cancer is among the most common types of neoplasias, and adenocarcinoma is the most frequent histological type. There is currently an extensive search for prognostic biomarkers of nonsmall cell lung cancer (NSCLC). METHODS: We analyzed the correlation of clinical data and patient survival with the levels of activated extracellular regulatory kinase (ERK) in histological samples of surgically resected early stage lung adenocarcinoma. We randomly selected 36 patients with stage I or II lung adenocarcinoma who underwent pulmonary lobectomy between 1998 and 2004. Patients were divided into the following two groups according to immunohistochemical profile: a group with <15% ERK-positive tumor cells and a group with ≥15% ERK-positive tumor cells. For data comparison, an enrichment analysis of a microarray database was performed (GSE29016, n=72). RESULTS: Activated ERK levels were ≥15% and <15% in 21 (58%) and 15 (42%) patients, respectively. There were no statistically significant differences in age, sex, smoking history, and body mass index (BMI) among the groups stratified by ERK levels. The survival rate was lower in the ERK ≥15% group than in the ERK <15% group (P=0.045). Enrichment analyses showed no correlation between variations in gene expression of ERK in patients with adenocarcinoma and survival rates in patients with stage I and combined stage II + III disease. CONCLUSIONS: Our findings suggest that high ERK positivity in cells from biological samples of lung adenocarcinoma is related with tumor aggressiveness and a poorer prognosis.
Authors: Joseph M Pepek; Junzo P Chino; Lawrence B Marks; Thomas A D'amico; David S Yoo; Mark W Onaitis; Neal E Ready; Jessica L Hubbs; Jessamy Boyd; Chris R Kelsey Journal: J Thorac Oncol Date: 2011-04 Impact factor: 15.609
Authors: Michel Jeanmart; Sylvie Lantuejoul; Frédéric Fievet; Denis Moro; Nathalie Sturm; Christian Brambilla; Elisabeth Brambilla Journal: Clin Cancer Res Date: 2003-06 Impact factor: 12.531
Authors: Suhaida A Selamat; Brian S Chung; Luc Girard; Wei Zhang; Ying Zhang; Mihaela Campan; Kimberly D Siegmund; Michael N Koss; Jeffrey A Hagen; Wan L Lam; Stephen Lam; Adi F Gazdar; Ite A Laird-Offringa Journal: Genome Res Date: 2012-05-21 Impact factor: 9.043
Authors: S Vicent; J M López-Picazo; G Toledo; M D Lozano; W Torre; C Garcia-Corchón; C Quero; J-C Soria; S Martín-Algarra; R G Manzano; L M Montuenga Journal: Br J Cancer Date: 2004-03-08 Impact factor: 7.640